{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":2,"total_is_capped":false,"direct_labels_cover":0,"predictions_cover":2,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12","author_layer_release":"2026-06-26"},"query_hash":"37f195c477b7","filters":{"venue":"Leukemia Supplements"}},"results":[{"id":"W2093253247","doi":"10.1038/leusup.2014.3","title":"STAT3 as a mediator of BCR-ABL1-independent resistance in chronic myeloid leukemia","year":2014,"lang":"en","type":"article","venue":"Leukemia Supplements","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto","funders":"National Institutes of Health; Brown University; Celgene; Gilead Sciences; Bristol-Myers Squibb","keywords":"Dasatinib; Nilotinib; Myeloid leukemia; Medicine; Cancer research; Imatinib mesylate; Imatinib; Tyrosine kinase; Leukemia; Immunology; Myeloid; Tyrosine-kinase inhibitor; Internal medicine; Cancer; Receptor","authors":[{"name":"Anna M. Eiring","is_ca":false},{"name":"Ira L. Kraft","is_ca":false},{"name":"Brent D. G. Page","is_ca":true},{"name":"Thomas O’Hare","is_ca":false},{"name":"Patrick T. Gunning","is_ca":true},{"name":"M. Deininger","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01031157572992444,"gpt":0.272663253366069,"spread":0.2623516776361446,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002136678,0.0001865131,0.0002640062,0.0002800817,0.0002420714,0.000457893,0.0002430683,0.0002749368,0.003553166],"category_scores_gemma":[0.0001475364,0.00008554498,0.0002394626,0.0002710432,0.0001998932,0.0001865581,0.0002300307,0.0006538657,0.0004824803],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004819868,"about_ca_system_score_gemma":0.0004237726,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007774501,"about_ca_topic_score_gemma":0.002020767,"domain_scores_codex":[0.9999024,0.00002154001,0.000006268292,0.00000745514,0.00003180003,0.00003043849],"domain_scores_gemma":[0.9999527,0.000009447367,0.00001320161,0.000005606837,0.000007143983,0.00001186146],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.009487245,0.001129215,0.004152373,0.0006716175,0.0001503805,0.000507455,0.0001246206,0.00110646,0.8334557,0.006237415,0.007152015,0.1358254],"study_design_scores_gemma":[0.003666829,0.008590574,0.0852575,0.0001715308,0.0005829023,0.002666324,0.0005386875,0.005089581,0.7594094,0.004790544,0.1291783,0.00005778041],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9595712,0.02187599,0.0008483166,0.001653987,0.0002186673,0.0000815666,0.0007940033,0.0001562292,0.01479999],"genre_scores_gemma":[0.9925067,0.003441717,0.0004013268,0.000198525,0.00004455626,0.00001742818,0.0004537792,0.00001020334,0.002925702],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003553166,"threshold_uncertainty_score":0.01188648,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2051100871","doi":"10.1038/leusup.2013.4","title":"Optimizing outcomes for patients with newly diagnosed multiple myeloma eligible for transplantation","year":2013,"lang":"en","type":"review","venue":"Leukemia Supplements","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Hotel Dieu Hospital","funders":"Celgene","keywords":"Bortezomib; Medicine; Thalidomide; Multiple myeloma; Lenalidomide; Dexamethasone; Regimen; Oncology; Maintenance therapy; Autologous stem-cell transplantation; Transplantation; Internal medicine; Cyclophosphamide; Surgery; Chemotherapy","authors":[{"name":"Philippe Moreau","is_ca":true},{"name":"Cyrille Touzeau","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04530592419364871,"gpt":0.3512608733916777,"spread":0.305954949198029,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006170556,0.0006107166,0.001868109,0.001075357,0.000189494,0.0005214948,0.0005270462,0.0006607119,0.003176485],"category_scores_gemma":[0.00202888,0.0001662365,0.001342245,0.001213828,0.0001683385,0.0004665368,0.0004441199,0.001165713,0.0002249897],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006994965,"about_ca_system_score_gemma":0.001276406,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002800141,"about_ca_topic_score_gemma":0.008693947,"domain_scores_codex":[0.99977,0.0000580092,0.00006289889,0.00003528369,0.00005193305,0.00002182683],"domain_scores_gemma":[0.9994028,0.0003541335,0.0001575568,0.000006297778,0.00005646969,0.00002289439],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0006027722,0.0001298133,0.001595214,0.06371848,0.001711668,0.00008650389,0.00004409805,0.0002935565,0.0003133344,0.0008133829,0.01755834,0.9131328],"study_design_scores_gemma":[0.002078155,0.001283583,0.03388802,0.1840975,0.02767162,0.002063307,0.0004815635,0.0005526497,0.001045248,0.004707709,0.7420256,0.0001051517],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.000309565,0.9990973,0.00002305743,0.0002271465,0.00005151172,0.000004156784,0.00002756956,0.000001737624,0.0002579226],"genre_scores_gemma":[0.00335113,0.9958112,0.0001674746,0.0003745869,0.00008695082,0.00001101795,0.00005335018,7.473296e-7,0.0001434672],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.003176485,"threshold_uncertainty_score":0.01062638,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}